[摘要] 目的 探究對中危肺栓塞患者进行抗凝治疗的疗效，并且对其可行性进行评价。 方法 方便选取2014年3月—2018年3月间来贵阳医院呼吸科接受住院治疗的肺栓塞患者64例进行该次的实验研究，所有的患者经肺栓塞严重指数评分为中度危险患者(Ⅲ级和Ⅳ级)每一级患者各有32例，在患者出院后用华法林治疗3个月，患者的治疗无明显差异。而后分析不同级别患者抗凝治疗的临床疗效、心肌损伤指标、血气分析以及患者的出血情况。 结果 Ⅲ级患者总有效率为96.88%，显著高于Ⅳ级患者75.00%，差异有统计学意义(P, 百拇医药
 [关键词] 肺栓塞严重指数;中危患者;抗凝治疗;疗效;可行性评价

 [中图分类号] R5 [文献标识码] A [文章编号] 1674-0742(2019)08(b)-0079-04

 [Abstract] Objective To investigate the efficacy of anticoagulant therapy in patients with moderate-risk pulmonary embolism and evaluate its feasibility. Methods Sixty-four patients with pulmonary embolism who were admitted to the Department of Respiratory Medicine of Guiyang Hospital from March 2014 to March 2018 were conveniently selected in this study. All patients underwent pulmonary embolism severity index as moderately dangerous patients (Class III and Class IV). There were 32 patients in each class. After the patients were discharged from hospital， they were treated with warfarin for 3 months. There was no significant difference in the treatment of the patients. Then， the clinical efficacy， myocardial injury index， blood gas analysis and bleeding of patients with different levels of anticoagulant therapy were analyzed. Results The total effective rate of class III patients was 96.88%， which was significantly higher than that of class IV patients， 75.00%， the difference was significant(P, 百拇医药(黄家胜 付英转 许蓉 罗倩 闵捷 谢本艳) 第 1 2 页 下一页
 百拇医药网 http://www.100md.com/html/paper/1674-0742/2019/23/25.htm